Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Conference News
Plain English
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Drugs In Clinical Trials

Important Notice: The Forum does not endorse any medical product or therapy. ALL medications and supplements should be taken ONLY under the supervision of a physician, due to the possibility of side-effects, drug interactions, etc.

Drug: ABBF (EVP6124)
Mode of action: α7 nAChR agonist
Phase: POC Successful
Company:
Note: Add-on for cognitive deficit; licensed in from Bayer

Useful Links:

Prickaerts J, van Goethem NP, Chesworth R, Shapiro G, Boess FG, Methfessel C, Reneerkens OA, Flood DG, Hilt D, Gawryl M, Bertrand S, Bertrand D, K├Ânig G. EVP-6124, a novel and selective a7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of a7 nicotinic acetylcholine receptors. Neuropharmacology . 2012 Feb ; 62(2):1099-110. Abstract

Boess FG, De Vry J, Erb C, Flessner T, Hendrix M, Luithle J, Methfessel C, Riedl B, Schnizler K, van der Staay FJ, van Kampen M, Wiese WB, Koenig G. The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents. J Pharmacol Exp Ther . 2007 May 1 ; 321(2):716-25. Abstract


November 25, 2014
SRF News
SRF Comments
Text Size
Reset Text Size
Share/Bookmark

See our latest webinar, Cognition and Treatment Resistance in Schizophrenia, held November 10, 2014.

See our last webinar, Research Domain Criteria (RDoC) Applied to Verbal Hallucinations, held May 28, 2014.
Copyright © 2005- 2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright